These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21031002)

  • 21. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mining for therapeutic gold.
    Collins FS
    Nat Rev Drug Discov; 2011 Jun; 10(6):397. PubMed ID: 21629277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs that made headlines in 2016.
    Keener AB
    Nat Med; 2016 Dec; 22(12):1377-1379. PubMed ID: 27923025
    [No Abstract]   [Full Text] [Related]  

  • 25. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macro trends in pharmaceutical innovation.
    Cohen FJ
    Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of FDA-approved new molecular entities: 1827-2013.
    Kinch MS; Haynesworth A; Kinch SL; Hoyer D
    Drug Discov Today; 2014 Aug; 19(8):1033-9. PubMed ID: 24680947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could pharma open its drug freezers?
    Mullard A
    Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
    [No Abstract]   [Full Text] [Related]  

  • 31. [Open innovation for Japanese pharmaceutical companies].
    Hoshino T
    Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):184-9. PubMed ID: 24107523
    [No Abstract]   [Full Text] [Related]  

  • 32. 2016 in review: FDA approvals of new molecular entities.
    Griesenauer RH; Kinch MS
    Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
    Kaitin KI; DiMasi JA
    Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological mechanism-based drug safety assessment and prediction.
    Abernethy DR; Woodcock J; Lesko LJ
    Clin Pharmacol Ther; 2011 Jun; 89(6):793-7. PubMed ID: 21490594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 37. Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries.
    Yashiro K; Lim Y; Sengoku S; Kodama K
    Drug Discov Today; 2023 Mar; 28(3):103483. PubMed ID: 36584874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Building a drug development database: challenges in reliable data availability.
    Audibert C; Romine M; Caze A; Daniel G; Leff J; McClellan M
    Drug Dev Ind Pharm; 2017 Jan; 43(1):74-78. PubMed ID: 27494335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.